Brigatinib Patent Expiration
Brigatinib is Used for treating anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It was first introduced by Takeda Pharmaceuticals Usa Inc
Brigatinib Patents
Given below is the list of patents protecting Brigatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Alunbrig | US10385078 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | Nov 10, 2035 | Takeda Pharms Usa |
| Alunbrig | US9611283 | Methods for inhibiting cell proliferation in ALK-driven cancers | Apr 10, 2034 | Takeda Pharms Usa |
| Alunbrig | US9012462 | Phosphorous derivatives as kinase inhibitors | Apr 28, 2031 | Takeda Pharms Usa |
| Alunbrig | US9273077 | Phosphorus derivatives as kinase inhibitors | May 21, 2029 | Takeda Pharms Usa |
Brigatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Brigatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
